TROP2 ADCs Available for Licensing

PREPARED BY Amass

DATE 2 September 2026

SECTIONS 4

SOURCES 192

Generated with Amass. Every claim in this report is cited; the sources are listed at the end.

Contents

TROP2 has become one of the most heavily pursued targets in oncology drug conjugates, with three programs already approved or in late-stage global registration and a large tail of clinical- and preclinical-stage assets moving through licensing deals at a rapid pace. This report answers a practical business-development question: of the TROP2-directed antibody-drug conjugates in development today — monospecific and bispecific alike — which ones, or which territorial/indication rights within them, remain genuinely open for a new licensing partner, as opposed to those already fully spoken for through prior transactions or corporate acquisitions?

The report proceeds in four parts. It first works through the deal and partnering status of clinical-stage TROP2 ADCs, covering approved/late-stage assets as well as earlier Phase 1–2 candidates from Western, Chinese, and Korean originators. It then turns to preclinical and discovery-stage TROP2 ADC programs, where platform companies frequently option or license assets before they reach the clinic. A third section surveys the broader TROP2 ADC intellectual-property estate and recent dealmaking benchmarks — patent concentration by assignee and the deal terms (upfronts, milestones, royalties, territory structures) seen across comparable transactions — to give context for valuing any open opportunity. The final section synthesizes these threads into a direct answer: which specific TROP2 ADC assets, or which regional/territory rights within already-partnered assets, are currently available to license.

Clinical-Stage TROP2 ADCs: Deal and Partnering Status

Approved and late-stage TROP2 ADCs

Three TROP2-directed ADCs have reached approval or late-stage global registration, and all three are now fully spoken for on a worldwide basis — though the paths there differ, and the residual "open" pieces are financial/funding arrangements rather than genuine unlicensed territories.

Sacituzumab govitecan (Trodelvy®), originated by Immunomedics, is FDA-approved (BLA 761115, approved 2020, with subsequent expansions including a 2025-era first-line TNBC/PD-L1 combination with pembrolizumab) [1] and EMA-approved (centralised authorization, MAH Gilead Sciences Ireland UC) [2] for triple-negative and HR-positive/HER2-negative metastatic breast cancer. Gilead Sciences acquired Immunomedics outright in 2020, giving it global rights ex-Asia. The remaining Asian rights were licensed to Everest Medicines in April 2019 (Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia, Mongolia) [3] [4] [5]; Gilead then reacquired those regional rights from Everest for a $280M upfront (up to $455M total) in August 2022, consolidating worldwide rights fully under itself [6] [7] [8] [9]. No territory or indication rights for sacituzumab govitecan remain open for licensing — it is fully unified with Gilead globally, including Greater China.

Datopotamab deruxtecan (Datroway®), a Daiichi Sankyo-originated TROP2 ADC built on Daiichi's DXd/deruxtecan payload technology, is approved by FDA (BLA 761394, accelerated approval in EGFR-mutated NSCLC plus TNBC and HR+/HER2- breast cancer indications) [10] [11] and EMA (centralised, MAH Daiichi Sankyo Europe GmbH, approved 2025 for HR+/HER2- breast cancer) [12]. Rights are governed by the global Daiichi Sankyo–AstraZeneca collaboration signed in July 2020, under which the companies co-develop and co-commercialize the drug worldwide and share costs/profits equally, except Japan, where Daiichi Sankyo retains exclusive rights [13] [14] [15] [16] — mirroring the structure of the same companies' HER2 ADC Enhertu

[17] [18] [19]. Datopotamab deruxtecan is thus fully partnered globally, with Japan carved out as Daiichi Sankyo's own retained territory — a structural regional split within an already-signed deal, not an open licensing opportunity.

Sacituzumab tirumotecan (sac-TMT, SKB264/MK-2870), originated by Kelun-Biotech (Sichuan Kelun Pharmaceutical), received NMPA approval in China in November 2024 for second-line-plus TNBC, the first domestically developed TROP2 ADC approved in China [20]. In May 2022, Kelun-Biotech licensed Merck (MSD) exclusive rights to develop, manufacture, and commercialize sac-TMT in all territories outside Greater China (Mainland China, Hong Kong, Macau, Taiwan) [20] [21] [22] [23]. Kelun-Biotech retains Greater China rights and continues its own registrational trials there, while Merck runs a global Phase 3 program (reportedly 15 ongoing Phase 3 studies) as monotherapy and in combination with Keytruda [23]. Merck has since brought in Blackstone Life Sciences as a non-dilutive R&D funder (up to $700M, royalty-only, no product rights) [22] [24], which does not alter the Kelun/Merck territorial split. The asset also sits within a much broader 2022–2023 Merck–Kelun-Biotech ADC alliance covering seven additional preclinical candidates under the same Greater-China carve-out [25] [26] [27]. Sac-TMT is therefore fully partnered worldwide (Merck ex-Greater China; Kelun-Biotech in Greater China) — the Greater China rights are not available for out-licensing, since Kelun-Biotech is actively commercializing there itself rather than seeking a partner.

All three approved/late-stage TROP2 ADCs are thus fully partnered or consolidated globally, and none presents a genuinely open, licensable territory or indication slot: Trodelvy is unified under Gilead worldwide; Datroway's only "regional split" is Daiichi Sankyo's own retained Japan rights within its AstraZeneca alliance; and sac-TMT's Greater China rights remain with originator Kelun-Biotech for its own commercialization. Any near-term licensing opportunities in the TROP2 ADC space are therefore concentrated in earlier-stage, monospecific or bispecific (e.g., TROP2/HER3, Nectin4/TROP2) clinical candidates rather than in this approved/late-stage tier.

Early/mid-clinical TROP2 ADCs from Western biotechs

Among Phase 1–2 TROP2-directed ADCs originated by Western (or Western-headquartered) biotechs, ownership ranges from fully out-licensed with no open territory remaining, to assets that still carry regional rights held by the originator, to genuinely wholly-owned and unpartnered programs.

LCB84 (LegoChem/LigaChem Biosciences) is fully out-licensed globally, with no open rights remaining. Built on LegoChem's ConjuAll platform using a TROP2 antibody in-licensed from the Italian firm Mediterranea Theranostic [28] [29], it entered a Phase 1/2 trial in US solid-tumor patients (including TNBC and colorectal cancer) in October 2023 [30]. In December 2023, LegoChem granted Janssen Biotech (J&J) an exclusive, worldwide license to develop and commercialize LCB84 for $100M upfront, a $200M option-exercise fee, and up to $1.7B in total potential milestones plus tiered royalties [28] [29] [30] [31], with J&J bearing sole responsibility for development/commercialization post option-exercise [31]. This is a complete global out-license — no territory or indication rights remain open.

OBI-992 (OBI Pharma / Biosion) presents a more layered picture. Its TROP2 antibody was discovered by Biosion via its SynTracer platform and in-licensed to OBI Pharma in December 2021; OBI Pharma holds an exclusive license to that antibody in all jurisdictions except Mainland China, Hong Kong and Macau, while Biosion retains exclusive rights in those territories [32] [33] [34]. The molecule (also called BSI-992) has reached Phase 1/2 (NCT06480240), evaluating safety/PK in solid tumors including NSCLC, SCLC and gastric cancer

[35] [36] [37]. The ex-China territory is thus already OBI Pharma's own asset rather than something out-licensed to a third pharma partner, while Greater China sits with Biosion — regional rights are already allocated between the two originators rather than genuinely "open." That said, OBI Pharma's own June 2025 corporate deck explicitly lists OBI-992 and OBI-902 among assets it intends to out-license "at early stages of clinical development" [38], indicating OBI is actively seeking a pharma partner for its ex-China rights — these are not yet signed to a big pharma partner.

OBI-902 (OBI Pharma) is a Phase 1/2, unpartnered program actively being shopped for a licensee. OBI's next-generation, glycan-conjugated (GlycOBI platform) TROP2 ADC (exatecan payload, DAR4) received FDA IND clearance in April 2025 and began Phase 1/2 dosing in September 2025, subsequently receiving orphan drug designations for cholangiocarcinoma and gastric/GEJ cancer [39] [40] [41] [42] [43]. OBI's own pipeline chart states it owns "global rights excluding China, Hong Kong, Macau, Taiwan, Japan, Korea, Singapore, Malaysia, Thailand, Turkey, and India" for at least one GlycOBI asset studied by a China-based partner (Asentawits Pharma) [44], indicating that OBI-902/992's Greater China and several Asian territories are already carved out to that regional partner. Meanwhile OBI explicitly frames itself as open for business development: its December 2025 investor deck lists OBI-992/OBI-902 (TROP2), OBI-904 (Nectin-4), OBI-201 (TROP2×HER2 bispecific) and OBI-221 (cMET×HER3 bispecific dual-payload) all as potential BD targets — "5 ADC products & 5 platform technologies" — with no global partner yet signed [38] [43]. This makes the OBI-902/OBI-992/OBI-201 franchise the clearest example of Western/Taiwanese-originated, clinical-stage TROP2 (and TROP2-bispecific) ADCs with open ex-Asia/global commercial rights still available for licensing, though the antibody itself carries the underlying territorial constraint from the Biosion license excluding Mainland China/HK/Macau [33].

OBI-201 (OBI Pharma), a TROP2×HER2 bispecific ADC built on the same GlycOBI platform and exatecan payload, remains in preclinical development per the evidence gathered, is not reported as licensed to any partner, and is grouped with the other OBI assets flagged for out-licensing [39] [43]. It should be treated as an open, unpartnered bispecific TROP2 asset from a Western-listed biotech, though it has not yet reached Phase 1 in the retrieved evidence — earlier-stage than the other candidates discussed here.

DB-1305/BNT325, though originated by the Suzhou-based DualityBio, is included here because its partner BioNTech is a German/Western company holding the ex-China commercial rights. This third-generation DITAC-platform, topoisomerase-1-inhibitor TROP2 ADC was licensed to BioNTech in August 2023, expanding an existing DualityBio–BioNTech partnership: BioNTech holds global commercial rights excluding Mainland China, Hong Kong and Macau, while DualityBio retains those Greater China rights [45] [46] [47] [48]. The asset (renamed sacituzumab drozuntecan) is in Phase 1/2, has FDA Fast Track designation, and is generating data in NSCLC, TNBC, ovarian and cervical cancer, including combination trials with BioNTech's BNT327 PD-L1×VEGF bispecific [45] [49] [50] [51] [52]. Because the global-ex-China rights are already with BioNTech, no additional Western-market licensing opportunity remains for DB-1305 — only the Greater China rights, still held by DualityBio, could theoretically be shopped to a China-focused partner, though no such deal was found in the retrieved evidence.

The search did not surface any additional wholly-unpartnered, Phase 1+ TROP2 monospecific ADC programs from other named Western originators: no confirmed Phase 1 TROP2 ADC candidate was found originating from Mersana, Zymeworks, or Sutro as a wholly-owned monospecific TROP2 asset (Sutro's only TROP2 program, ASP2998, is an already-partnered Astellas iADC collaboration in the clinic, and Sutro's wholly-owned pipeline — STRO-004/006/227 — targets Tissue Factor, integrin β6 and PTK7, not TROP2) [53] [54] [55] [56]. Nor was evidence retrieved confirming an open license for the Greater China territory of DB-1305, or confirming

whether OBI Pharma's ex-Asia rights to OBI-992/OBI-902 have since been signed to a named pharma partner beyond the "potential BD deals" language in its own investor materials; this section reflects status as of the retrieved sources and may not capture deals announced afterward.

In sum: LCB84 (LegoChem/J&J) is fully out-licensed worldwide with no open rights [28] [30]; OBI-992 has its ex-China rights held by OBI (unpartnered further, flagged for BD) and China/HK/Macau held by Biosion [32] [33] [38]; OBI-902 is Phase 1/2, unpartnered, and actively marketed for licensing per the company's own BD materials, with its underlying antibody excluding Mainland China/HK/Macau [40] [41] [43]; OBI-201 is a preclinical, unpartnered TROP2×HER2 bispecific flagged for BD [39] [43]; and DB-1305/BNT325 has its global ex-Greater-China rights already with BioNTech, with Greater China retained by DualityBio and no further Western licensing opportunity identified [46] [48].

Early/mid-clinical TROP2 ADCs from Chinese/Korean biotechs

A clear pattern emerges among Chinese- and Korean-originated TROP2 ADCs: most that have reached Phase 1–2 have already done ex-China (or ex-Greater China) deals with Western pharma, while the originator retains Greater China (and sometimes broader Asian) commercial rights. A few remain wholly unpartnered.

JSKN016 (Alphamab Oncology, TROP2/HER3 bispecific ADC) has progressed to Phase III in triple-negative breast cancer in China alongside an ongoing Phase Ib China study and a Phase I Australian study of a subcutaneous formulation [57] [58]. In August 2026, Alphamab licensed Pathos AI exclusive rights to research, develop, manufacture and commercialize JSKN016 in all territories outside Chinese mainland, Hong Kong, Macau and Taiwan, for a $125M upfront and up to ~$2.1B in milestones plus tiered royalties [57] [59] [60] [61]. Alphamab explicitly retains full and exclusive Greater China rights [57] [59] [61], so those rights are no longer "available to license" in the open sense — they sit with the originator itself rather than constituting an out-licensable open territory, though Alphamab could in principle still sub-license within that retained territory.

GQ1010 (GeneQuantum, TROP2 ADC using iLDC conjugation) was out-licensed for global rights excluding Greater China (mainland China, Hong Kong, Macau, Taiwan) to US biotech Pyramid Biosciences in April 2023, for a $20M upfront and up to $1B in milestones plus tiered royalties [62] [63]. Pyramid's asset was subsequently absorbed into Biohaven's pipeline as BHV-1510/PBI-410/PBI-200-related program, now in Phase 1/2 combined with cemiplimab, showing activity in NSCLC, endometrial, and other tumors [64] [65]. Separately, China-based Kai Tak Pharmaceutical filed a clinical trial application for GQ1010 in China (accepted by CDE February 2024) [65], and a China Phase I/II trial (CTR20241614) sponsored by GeneQuantum itself dosed its first subject in August 2024 [64] [66]. Greater China rights for GQ1010 thus remain with GeneQuantum (via its own clinical program and/or the Kai Tak relationship) and were not included in the Pyramid/Biohaven deal — making Greater China an open/retained territory, though the evidence does not clarify whether Kai Tak holds an exclusive China license or is a co-development/CRO-style partner, nor does it show any further ex-China sub-partner beyond Pyramid/Biohaven.

Sac-TMT/SKB264 (Kelun-Biotech, now MK-2870) is already approved in China across multiple indications (2L+ TNBC, 2L NSCLC, and HR+/HER2- breast cancer) [20] [67] [68], making it the most advanced Chinese TROP2 ADC — as covered above, Kelun-Biotech licensed all rights outside Greater China to Merck in May 2022 [69] [70], retaining Greater China rights and continuing to market/develop domestically [20] [68] [69]. This ex-Greater-China-to-Merck / domestic-retained template was extended in a broader 2026 agreement covering seven additional preclinical ADC candidates, again with Kelun-Biotech retaining mainland China/Hong Kong/Macau rights [25].

Since sac-TMT is already approved and Kelun is actively commercializing in Greater China, this is a mature domestic franchise rather than an open licensing opportunity, though it illustrates the same regional carve-out pattern seen in Kelun-Biotech's later ADC deals with Merck.

ESG401 (Shanghai Escugen Biotechnology / Levena Biopharma, TROP2-SN38 ADC) was originally co-developed by Escugen and Levena (a Sorrento Therapeutics subsidiary), with the two originally jointly owning domestic and international patents and sharing global rights [71] [72] [73]. ESG401 progressed through Phase 1 (with published Phase 1a data) [74] to Phase III in China for TNBC, sponsored by Escugen [75]. Ownership has since become complicated by Sorrento's corporate distress: patent/database records show licensing organizations including "Oqory, Inc." and "Vincerx Pharma, Inc." now associated with the asset, with a December 2024 note referencing Vincerx Pharma announcing developments tied to Escugen/Levena [76] [77] [78]. The retrieved evidence does not clarify the current territorial split — whether Vincerx or Oqory hold ex-China rights while Escugen retains China, or whether global rights remain jointly held/unresolved following Sorrento's bankruptcy proceedings. No clean ex-China licensing announcement analogous to the JSKN016/GQ1010/sac-TMT deals was found for ESG401; its ownership structure appears more fragmented and should be flagged as unresolved rather than assumed open.

Alphamab's approach with JSKN016 mirrors its earlier JSKN003 (HER2 bispecific ADC) deal, where mainland China rights were separately licensed to CSPC/JMT-Bio [79] [80] — showing Alphamab is willing to license *within* Greater China to sub-partners even after granting ex-Greater-China rights elsewhere. This suggests the "retained" Greater China territory for JSKN016 (and, by pattern-matching, potentially other Alphamab bispecific ADCs) could itself be further sub-licensed to a domestic partner, though no such domestic sub-license for JSKN016 was found in the retrieved evidence.

On the Korean side, **LCB84 (LegoChem Biosciences)** — the same asset discussed above, built on LegoChem's platform with a TROP2 antibody licensed from Italian biotech Mediterranea Theranostic and in Phase 1/2 in the US [81] [82] — was granted to Janssen Biotech (J&J) in December 2023 as an exclusive, worldwide license, i.e., global with no territory carve-out for Korea or Greater China [28] [81] [82] [83]. This is a fully out-licensed global asset with no open regional rights remaining, distinct from the Chinese pattern of Greater-China retention.

Beyond these, ABL Bio and LigaChem (formerly LegoChem) have expanded bispecific ADC collaboration, and LigaChem's broader pipeline (seven ADC programs including TROP2) mixes out-licensed assets (LCB14, LCB71, LCB73) with wholly-owned early candidates, but the retrieved evidence does not specify a distinct TROP2-directed bispecific asset with a described territory split beyond LCB84 [84] [85]. No specific evidence was retrieved on a Nectin4/TROP2 bispecific ADC from a Chinese or Korean originator, which remains a gap in the search results.

Taken together, the territory status across this cohort is: **JSKN016** (Alphamab) — ex-Greater-China licensed to Pathos AI, Greater China retained by Alphamab [57] [59] [61]; **GQ1010** (GeneQuantum) — ex-Greater-China licensed to Pyramid/Biohaven, Greater China retained/being developed by GeneQuantum (and possibly Kai Tak) [62] [63] [65] [66]; **sac-TMT/SKB264** (Kelun-Biotech) — ex-Greater-China licensed to Merck, Greater China retained and already commercialized by Kelun-Biotech, mature/approved and not an open opportunity [25] [68] [69]; **LCB84** (LegoChem) — fully global exclusive license to Janssen, no open territory remains [28] [81] [82]; and **ESG401** (Escugen/Levena) — ownership/territory status unclear and unresolved in retrieved evidence following Sorrento's financial distress and the apparent involvement of Vincerx Pharma and Oqory, such that no territory can be confirmed as genuinely open for a new licensee [76] [77] [78].

The dominant deal structure among Chinese originators (Alphamab, GeneQuantum, Kelun-Biotech) is ex-Greater-China out-licensing to a Western partner with Greater China retained by the originator — meaning Greater China is technically "open" only in the sense that the originator itself still holds and could further sub-license it, not that it is unclaimed. LegoChem's LCB84 is the clearest case of a fully out-licensed, no-remaining-territory deal. ESG401's status is the most uncertain and would need further primary-source verification beyond what was retrieved here.

Preclinical and Discovery-Stage TROP2 ADC Programs

Platform-company and discovery-stage TROP2 ADC candidates

The preclinical/discovery-stage TROP2 ADC landscape is dominated by Chinese ADC platform companies that generate candidates internally and then out-license them regionally, retaining Greater China rights while granting global-ex-China (or ex-Greater-China) rights to Western biotech partners. Across every asset identified in this research, essentially every named preclinical TROP2 (or TROP2-bispecific) construct with disclosed originator commentary has already been optioned or licensed under an exclusive agreement — none of the major platform players surfaced in this search currently market a specific, named TROP2 ADC as openly available.

VelaVigo's Nectin4/TROP2 bispecific ADC (AVZO-103/VBC103) illustrates the pattern. VelaVigo, a Shanghai/Boston multispecific-antibody and ADC discovery biotech, granted Avenzo Therapeutics an exclusive option in November 2024 that converted into an exclusive global license (excluding Greater China) to develop, manufacture and commercialize this first-in-class Nectin4/TROP2 bispecific ADC [86] [87] [88]. VelaVigo retains Greater China rights and is eligible for up to ~$750 million in milestones plus tiered royalties on Avenzo's territory [86] [89]. The molecule has since advanced into Phase 1/2 trials as AVZO-103/VBC103, moving it past the discovery stage and fully committed under this option/license structure [90] [91]. VelaVigo's broader multispecific/ADC pipeline (10+ FIC/BIC molecules) is being advanced via a "BD+VC" out-licensing model, and a second deal — VBS-102, a bispecific antibody rather than a TROP2 ADC — has already been struck with Ollin Biosciences, indicating the company continues to actively shop residual pipeline assets even though no additional TROP2-specific candidate beyond the Avenzo deal was identified as explicitly "available" [92].

GeneQuantum Healthcare, a Suzhou-based bioconjugation-platform company built on its proprietary iLDC (intelligent Ligase-Dependent Conjugation) site-specific enzymatic technology, licensed the global rights (excluding Greater China) to its preclinical TROP2 ADC GQ1010 to Pyramid Biosciences in April 2023, for a $20 million upfront and up to $1 billion in milestones plus tiered royalties [63] [93] [94]. At the time of the deal GQ1010 was preclinical, benchmarked as superior to datopotamab deruxtecan in tumor growth inhibition and cytotoxicity in preclinical models [95]; it has since progressed into Phase 1/2 trials under the Pyramid/Biohaven umbrella as BHV-1510 [64] [96]. GeneQuantum's other pipeline TROP2 asset, GQ1003, appears in the company's platform listings as a TROP2-targeting ADC built on the same iLDC platform [97], but the retrieved evidence contains no licensing announcement, option, or explicit "available for out-licensing" statement for it — its status as in-house, unpartnered, or otherwise cannot be confirmed. GeneQuantum has separately shown a pattern of licensing its *platform technology* rather than named assets — a non-exclusive conjugation-technology collaboration with InxMed [98] and a Phase 3 HER2 ADC out-license to Henlius [99] — which reinforces that its business model is active out-licensing, even though no unpartnered TROP2 molecule was explicitly flagged as open.

Biosion, a global biologics discovery company built on its proprietary SynTracer high-throughput endocytosis platform, licensed its anti-TROP2 mAb BSI04702 to OBI Pharma in December 2021 for worldwide rights excluding China, specifically to enable its development as an ADC (subsequently OBI-992/BSI-992) [32] [100] [101]. Biosion retained China rights [32]. This transaction occurred at the naked-antibody stage, before ADC conjugation and clinical entry, making it a clear example of a discovery-stage TROP2 asset that was licensed out rather than retained for shopping. Biosion has continued this exclusive-licensing model with other pipeline assets, including its TSLP/IL4R bispecific licensed to Aclaris [102] [103] [104], confirming an active out-licensing business but with the specific TROP2 antibody already committed to OBI Pharma.

Alphamab Oncology's JSKN016, a TROP2/HER3 bispecific ADC, has already reached Phase 3 in China and is therefore not strictly discovery-stage, but it is worth noting here as a bispecific TROP2 platform asset whose ex-Greater-China rights were only recently (August 2026) licensed to Pathos AI for $125 million upfront plus up to ~$2.09 billion in milestones and tiered royalties [57] [59] [105] [106]. Alphamab retains full rights in Chinese Mainland, Hong Kong, Macau and Taiwan [106], again illustrating the regional-carve-out pattern that recurs across this space; the asset is no longer open for ex-China licensing.

Escugen Biotechnology's ESG401, an SN-38-conjugated anti-TROP2 IgG1, is jointly developed and co-owned by Escugen and Levena (a Sorrento subsidiary offering ADC linker/payload/conjugation platform services), with the two companies sharing global rights rather than out-licensing to a third party [71] [107] [108] [109]. This is a co-development/co-ownership structure rather than an open-for-licensing posture, and the asset has already progressed into Phase Ib/II trials, placing it beyond the discovery stage [108] [109].

A handful of programs remain ambiguous for lack of documentation rather than confirmed availability. Lanier Biotherapeutics' preclinical TROP2 ADC and RemeGen's biparatopic TROP2 ADC both appear in patent/pipeline databases as preclinical-stage, originator-owned assets with no listed licensing organization, which could suggest they remain unpartnered [110] [111]. However, the retrieved evidence contains no explicit statement from either company that these programs are being marketed for licensing, so their availability cannot be confirmed — this is a gap in the evidence rather than a confirmed "open" status. Shanghai Tangling Biomedicine's TROP2 ADC (built on its GlycanLink Biotech platform) likewise shows no listed licensee but no explicit "available for licensing" statement either [112]. Levena Biopharma, positioning itself as a CRO/CDMO "ADC specialty company," explicitly advertises that it has "a portfolio of proprietary toxins available for testing and licensing upon request," but this refers to Levena's payload/linker/screening technology platform generally, not to a specific named TROP2 ADC candidate being shopped [113].

Taken together, every specifically named preclinical/discovery TROP2 (or TROP2-bispecific) ADC candidate for which the retrieved evidence documents a clear originator-partner relationship — VelaVigo's Nectin4/TROP2 bispecific, GeneQuantum's GQ1010, Biosion's BSI04702, and Alphamab's JSKN016 — has already been optioned or exclusively licensed under a defined regional-carve-out structure, typically ex-Greater-China rights to the licensee with the Chinese originator retaining domestic rights and future royalty/milestone economics. No source retrieved in this research explicitly states that a specific, named preclinical TROP2 ADC molecule remains open and unpartnered for global or regional licensing; where "available for licensing" language does appear, as with Levena Biopharma, it refers to platform technology or toxins rather than a discrete TROP2 ADC asset. Programs such as Lanier's and RemeGen's preclinical TROP2 ADCs lack a disclosed licensee in the records retrieved, which may indicate they are still unpartnered, but this cannot be confirmed as active out-licensing marketing given the available evidence.

TROP2 ADC IP Estate and Recent Dealmaking Benchmarks

TROP2 ADC patent estate by assignee

The IP landscape for TROP2-directed ADCs is moderately concentrated around a small number of foundational antibody/linker-payload families, layered with a fast-growing tail of newer antibody, bispecific, and next-generation payload filings—mostly from Chinese biotechs entering the space post-2020.

The most defensive, blocking position belongs to **Daiichi Sankyo/Sapporo Medical University**. The core anti-TROP2 antibody-drug-conjugate family (priority date 2013-12-25, underlying datopotamab deruxtecan/Dato-DXd) is the most heavily prosecuted single family in the space, with dozens of national-phase grants and continuations spanning Korea, the US, and other jurisdictions, and it remains in active prosecution through 2025 [114] [115] [116] [117] [118]. This foundational patent covers the anti-TROP2 antibody conjugated via Daiichi's proprietary GGFG-tetrapeptide-based cleavable linker to an exatecan-derivative topoisomerase-I-inhibitor payload – the same linker-payload platform underlying Daiichi's other DXd ADCs [116]. Daiichi Sankyo (now with AstraZeneca as co-filer following their global collaboration) has since built a dense secondary patent thicket around this core: manufacturing/DAR-control methods [119], dosing regimens [120], combination therapies with PARP inhibitors [121], ATR inhibitors [122], DNMT inhibitors [123], bispecific checkpoint inhibitors [124] [125], anti-PD-1/TIM-3 bispecifics [126], and companion-diagnostic scoring methods for patient selection [127] [128], plus a newly filed 2024-priority combination patent pairing an anti-TROP2 ADC with an anti-HER2 ADC [129]. This breadth of method-of-use/combination patents functionally extends exclusivity well beyond the base composition-of-matter claims and creates significant freedom-to-operate (FTO) complexity for any party trying to combine a TROP2 ADC with common combination partners.

Gilead Sciences, via its acquisition of Immunomedics, holds the IP estate behind sacituzumab govitecan. This estate is focused less on core antibody composition (largely off-patent or near-expiry legacy claims) and more on a broad set of combination and use patents: bladder-cancer intravesical administration [130], combinations with adenosine-pathway inhibitors/etrumadenant with Arcus Biosciences [131] [132] [133], androgen-receptor-signaling-inhibitor combinations in prostate cancer [134], and MCL-1 inhibitor combinations [135] [136] [137] [138]. This gives Gilead a wide combination-therapy fence around SN-38-linker TROP2 ADCs even where the base antibody patents are aging.

Beyond these two incumbents, a large second wave of assignees has filed independent TROP2 antibody or ADC composition patents, indicating that the antibody-binder space is not exclusively controlled by Daiichi/Gilead. CSPC Megalith Biopharmaceutical (formerly CSPC Dophen) holds a family of anti-TROP2 antibodies and ADCs with a 2019 priority date and continued prosecution through 2025 [139] [140] [141]. Bio-Thera Solutions has a maytansinoid-payload anti-TROP2 ADC family (2017 priority) [142] [143] plus newer treatment-method and drug-conjugate patents (2021–2022 priority) [144] [145] [146] [147]. Biosion Inc. holds both conventional and heavy-chain-only (nanobody) anti-TROP2 antibody families usable as ADC binders or bispecific building blocks [148] [149] [150]. Fortvita Biologics has filed monospecific TROP2 ADC compositions [151] as well as bispecific B7-H3/TROP2 [152] and, with Innovent Biologics, TROP2/B7-H4 bispecific ADC constructs [153]. Sichuan Kelun-Biotech (Merck's partner on the sac-TMT/SKB264-class exatecan ADCs) is active in the broader bispecific-ADC linker space through its EGFR/c-MET bispecific ADC filings [154] [155] [156], indicating in-house bispecific ADC linker-payload capability that could extend to TROP2 constructs. Beijing/JOINN Biologics has filed camptothecin-analog immunoconjugate linker chemistry explicitly naming anti-TROP2 antibodies [157] [158].

Bispecific TROP2 ADC constructs form a fragmented, emerging sub-landscape in which no single assignee dominates; instead, multiple independent groups have filed overlapping but non-identical bispecific pairings, suggesting whitespace but also fragmentation risk for licensees. Biocytogen Pharmaceuticals holds anti-HER2/TROP2 bispecifics and ADCs, plus a related uniform-DAR conjugation method and a PTK7/TROP2 bispecific family [159] [160] [161] [162] [163]. Bright Biologics/Hangzhou Bailite Biopharmaceutical holds anti-HER2/TROP2 bispecific antibodies [164] [165]. Xadcera Biopharmaceutical holds anti-TROP2/EGFR bispecific antibodies and derived ADCs [166] [167]. Innovent/Fortvita cover TROP2/B7H4 [153], and Fortvita alone covers B7-H3/TROP2 [152]. WuXi Biologics also holds an engineered anti-TROP2 antibody/ADC hinge-engineering patent usable in either monospecific or bispecific formats [168].

Academic and platform-technology assignees add further complexity to the picture. University of Texas holds both antibody-combination patents (TROP2 ADC plus DNMT/Zeb1 inhibitor) [169] [170] and a newer TROP2-targeting antibody composition family (2024 priority, with Tsuchikama/An inventors known for click-chemistry conjugation platforms) [171]. The Agency for Science, Technology and Research (A*STAR, Singapore) has filed both conventional and bispecific/CAR/BiTE-compatible anti-TROP2 antibody families [172] [173] [174]. TAE Life Sciences holds Fc-engineering/site-specific-conjugation IP (an L234A/L235A/L328C triple mutant) explicitly applicable to TROP2 among other targets, which could be a cross-cutting FTO consideration for any conjugation-platform licensee [175] [176] [177]. Hummingbird Bioscience has a newly filed (2024-priority) TROP2-binding-molecule/linker-payload family still in early prosecution [178].

Overall, the landscape is bifurcated. On one side sits a highly concentrated core around Daiichi Sankyo/AstraZeneca's foundational GGFG-linker/exatecan-payload composition and its extensive combination/use-patent halo, which any party seeking to in-license a topoisomerase-I-payload TROP2 ADC with a similar chemotype must navigate for FTO, alongside a comparably fenced Gilead/Immunomedics combination-therapy estate around the SN-38-linker chemotype. On the other side sits a fragmented, rapidly expanding periphery of 15+ additional assignees — mostly Chinese biotechs, several academic/platform players, and multiple independent bispecific-construct filers — covering alternative antibody epitopes, novel linker-payload chemistries (maytansinoids, belotecan/camptothecin analogs, NMT inhibitors [179] [180]), and bispecific TROP2 combinations with HER2, EGFR, B7-H3, B7-H4, PTK7, and CD44v9. This structure means core FTO risk concentrates on the incumbents' composition and combination claims, while genuine antibody/bispecific-construct whitespace still exists for differentiated binders and novel payload chemistries — a key factor in assessing what remains realistically licensable versus encumbered.

Recent TROP2 ADC licensing deal terms

Recent TROP2-directed ADC and TROP2-bispecific ADC licensing transactions show a highly consistent template: a modest upfront/near-term payment, a very large biobucks milestone package (often 10–20x the upfront), tiered royalties scaling from mid-single-digit to low-double-digit percentages, and a territory carve-out in which the Chinese originator retains Greater China (or mainland China/Hong Kong/Macau/Taiwan) rights while the licensee gets the rest of world — or, occasionally, truly global rights.

The benchmark deal for a clinical-stage TROP2 monospecific ADC is **Merck/MSD's agreement with Kelun-Biotech for SKB-264 / sacituzumab tirumotecan (sac-TMT)**. Merck exercised its option for ex-Greater-China rights in 2022 for a $30M option-exercise payment plus $30M and $25M in near-term technology-transfer/project payments, with milestone potential of $90M in development, $290M at first commercial sale, and $780M in sales-based milestones for the TROP2 program, alongside tiered royalties ranging from mid-

single-digit to low-double-digit on net sales [21] [70]. Kelun-Biotech kept rights to mainland China, Hong Kong, and Macau [21] [181]. This arrangement was embedded in a broader 2022–2023 seven-ADC master license (this TROP2 asset plus six others), which itself carried a $175M upfront and up to $9.3B in aggregate milestones ($1.0B development, $2.8B regulatory, $5.5B sales) with the same mid-single- to low-double-digit tiered royalty structure and the same Greater China retention pattern [21] [181]. Most recently (Nov 2025), Merck brought in Blackstone Life Sciences as a non-dilutive financing partner for sac-TMT, paying Blackstone royalties in the low- to mid-single digits on net sales in Merck's territories in exchange for upfront-like funding – illustrating a further monetization layer built on top of the original territory-split license, without altering Kelun's underlying agreement [182] [183].

By contrast, **Janssen (J&J)'s deal with LegoChem Biosciences for LCB84** was a fully global, single-buyer transaction rather than a territory split: LegoChem granted Janssen worldwide exclusive rights, structured as $100M upfront plus a $200M option-exercise payment, with the remainder of a potential $1.7B total ($1.422B in aggregate milestones) tied to development, regulatory, and commercial milestones plus tiered royalties on net sales [28] [184] [185]. Janssen took over sole clinical and commercial responsibility after option exercise, while collaborating with LegoChem through the Phase 1/2 stage [28].

A comparable Chinese-origin ADC platform deal – illustrative of the architecture LaNova has used across its ADC and bispecific programs – is **AstraZeneca's agreement with LaNova Medicines for LM-305**, a GPRC5D ADC: $55M upfront/near-term payments, up to $545M in development/commercial milestones, and tiered global royalties, again on a fully global exclusive license rather than a territory carve-out [186] [187] [188].

The clearest recent bispecific TROP2 comparable is **Pathos AI's deal with Alphamab Oncology for JSKN016 (TROP2/HER3 bispecific ADC)**: a $125M upfront payment, up to ~$2.1B in development/commercialization milestones, and tiered royalties at high-single-digit to low-double-digit rates on net sales in Pathos's territory, with Alphamab retaining full rights in mainland China, Hong Kong, Macau, and Taiwan [59].

Avenzo Therapeutics' agreement with VelaVigo for a Nectin4/TROP2 bispecific ADC used an option-based structure rather than a straight license: Avenzo received an exclusive option to an exclusive license covering global rights excluding Greater China, with VelaVigo retaining Greater China and collaborating on global development. Total potential milestones were disclosed at ~$750M plus tiered royalties on sales in Avenzo's territory; upfront/option-exercise economics were not separately broken out in the release [86].

Cross-deal context from the broader China-outbound ADC wave reinforces the template: Roche's ex-China license for Hansoh's CDH17 ADC was worth up to $1.45B [189]; Roche's deal with Innovent for a DLL3 ADC used $80M upfront plus $1B in milestones and royalties, again ex-China [190]; BMS's agreement with Biokin for a HER3/EGFR bispecific ADC reached $8.4B total including $800M upfront [191]; and BioNTech's deal with Duality Bio for two ADCs used $170M upfront with >$1.5B in milestones on global rights excluding mainland China/Hong Kong/Macau [191]. Industry analysis of the broader China-outbound ADC licensing wave (2024–2025, >$30B in aggregate deal value) confirms typical upfronts of $20M–$100M with milestone-heavy structures reaching $500M–$5B+ and the persistent pattern of licensors retaining Greater China rights [192].

Several benchmark takeaways follow for currently unpartnered or regionally-open TROP2 (and TROP2-bispecific) ADC assets. Upfronts for clinical-stage or option-based TROP2 ADC deals have clustered in the $30M–$125M range, with the largest (LegoChem/J&J at $100M plus a $200M option fee) reserved for an asset already in Phase 1/2 [21] [28] [59]. Total biobucks potential scales from roughly $600M for preclinical assets up to $1.7B–$2.1B+ for clinical-stage or bispecific/dual-target differentiated assets, and into the multi-billion

range for master-license/multi-asset packages such as Kelun's seven-ADC deal at $9.3B [21] [59] [181] [186]. Royalties are consistently tiered, spanning mid-single-digit to low-double-digit percentages of net sales, sometimes stacked with third-party royalty carve-outs — as with Blackstone's low-to-mid-single-digit slice layered on top of Merck's own royalty obligation to Kelun [21] [59] [182]. Territory structuring is the dominant variable: most Chinese-originated TROP2 (and TROP2-bispecific) assets are licensed ex-Greater China, with the originator retaining mainland China/Hong Kong/Macau(/Taiwan) rights [21] [59] [86], whereas non-Chinese originators such as LegoChem have transacted fully worldwide rights [28]. This implies that assets still carrying open Greater China (or other regional) rights after an ex-China deal represent a distinct, still-available licensing opportunity, priced against these same milestone/royalty benchmarks but typically at a smaller regional-rights upfront.

Synthesis: Which TROP2 ADCs Are Currently Available to License

Across all three tiers examined — approved/late-stage, clinical-stage, and preclinical/discovery — a single structural pattern recurs so consistently that it, more than any individual asset, defines the TROP2 ADC licensing landscape: Chinese (and increasingly Taiwanese/Korean) originators develop the molecule, license ex-Greater-China (or global-ex-China) commercial rights to a Western partner, and retain Greater China for themselves, either to commercialize directly or to sub-license domestically. Layered on top of this is a small set of genuinely global, no-carve-out transactions (LegoChem/Janssen, Daiichi Sankyo/AstraZeneca), and a residual handful of assets that have not yet been placed with any partner at all. Sorting "available to license" from "already committed" therefore requires distinguishing three different senses of "open": (1) a molecule with no signed partner anywhere, (2) a molecule that is partnered ex-China but whose Greater China rights sit with an originator who is *not* actively commercializing there and could still license out, and (3) a molecule whose apparent regional split is illusory because the "retaining" party is already commercializing or otherwise not shopping that territory.

Fully committed, no opportunity. The three approved/late-stage TROP2 ADCs — sacituzumab govitecan (Trodelvy, unified globally under Gilead) [1] [2] [6] [7] [8] [9], datopotamab deruxtecan (Datroway, Daiichi Sankyo/AstraZeneca globally, Japan retained by Daiichi within that same alliance) [10] [12] [13] [14], and sacituzumab tirumotecan (sac-TMT, Merck ex-Greater-China / Kelun-Biotech in Greater China, where Kelun is already commercializing) [20] [21] [22] [23] — present no genuine open territory or indication. The same logic extends to two clinical-stage assets: LCB84, fully and globally out-licensed to Janssen with no carve-out [28] [30] [31], and DB-1305/BNT325, whose ex-Greater-China rights already sit with BioNTech, leaving only a theoretical, unconfirmed Greater China opportunity with DualityBio [45] [46] [47] [48]. JSKN016 (Alphamab/Pathos AI) and GQ1010 (GeneQuantum/Pyramid-Biohaven) fall into the same "committed ex-China" bucket, though each leaves a residual Greater China question addressed below [57] [59] [61] [62] [63].

Genuinely available. The clearest, best-evidenced open assets are OBI Pharma's TROP2 franchise: OBI-902 (Phase 1/2, IND-cleared, exatecan/GlycOBI platform) and OBI-992/BSI-992 (Phase 1/2), both explicitly named in OBI's own late-2025 investor materials as targets for business development, alongside the preclinical TROP2×HER2 bispecific OBI-201 [38] [39] [40] [41] [43]. These are the only assets in the entire dataset for which an originator has publicly and explicitly stated an intent to out-license a *named* clinical-stage TROP2 (or TROP2-bispecific) molecule, rather than that status being inferred from the absence of a deal announcement. The rights on offer are not unencumbered, however: the underlying antibody license from Biosion already excludes

Mainland China/Hong Kong/Macau [32] [33], and at least one related GlycOBI asset shows a further Asian carve-out to a regional partner [44], so any incoming licensee would be acquiring an ex-Greater-China/ex-several-Asian-markets position, not true global rights.

Ambiguous — plausibly open but unconfirmed. A second tier consists of assets whose absence of a disclosed licensee may reflect genuine availability or simply gaps in public disclosure. GeneQuantum's second TROP2 candidate, GQ1003, appears in platform pipeline listings with no licensing announcement [97]; Lanier Biotherapeutics' and RemeGen's preclinical TROP2 ADCs, and Shanghai Tangling Biomedicine's GlycanLink-based TROP2 ADC, likewise show no listed partner but also no explicit "available for licensing" statement [110] [111] [112]. Levena Biopharma advertises licensable payload/linker technology generally, not a discrete TROP2 ADC asset [113]. None of these can be confidently classed as "available" on the strength of the evidence gathered.

Retained-but-not-really-open territories. The dominant deal architecture — ex-Greater-China license out, Greater China retained by the originator — creates a large set of territories that are nominally unlicensed but not realistically available to a new entrant, because the retaining party is either already commercializing there (sac-TMT/Kelun-Biotech [20] [68]) or shows no signal of seeking a partner (Alphamab's Greater China JSKN016 rights [57] [59] [61], though Alphamab's precedent of sub-licensing JSKN003's China rights to CSPC/JMT-Bio suggests such further sub-licensing is not out of the question [79] [80]). GeneQuantum's Greater China rights to GQ1010 are the partial exception: GeneQuantum is running its own China trial and/or working with Kai Tak Pharmaceutical, but the exact exclusivity of that relationship — and thus whether GQ1010's China rights remain licensable to a third party — is unconfirmed [62] [64] [65] [66]. VelaVigo's Nectin4/TROP2 bispecific follows the identical pattern: ex-Greater-China rights are with Avenzo (now in Phase 1/2 as AVZO-103/VBC103), Greater China retained by VelaVigo, with no evidence of further shopping [86] [87] [90] [91]. ESG401 is the one asset whose territorial status cannot be characterized at all given Sorrento's bankruptcy and the tangled subsequent involvement of Vincerx and Oqory — it should be flagged as unresolved rather than counted as open in either direction [76] [77] [78].

What "available" would cost. The dealmaking benchmarks give a pricing frame for whatever genuinely does surface — whether OBI's ex-Asia rights, a sub-licensed Greater China slice, or a newly disclosed preclinical candidate. Clinical-stage, ex-China licenses have clustered at $20M–$125M upfront with $600M–$2.1B+ in total milestones and mid-single- to low-double-digit tiered royalties (GQ1010/Pyramid at $20M upfront/$1B milestones [63]; sac-TMT/Merck's tranche at $30M option fee/$90M–$780M in tiered milestones within a larger $9.3B master deal [21] [181]; JSKN016/Pathos AI at $125M upfront/~$2.1B milestones [59]), while a fully global, no-carve-out deal for an asset already in the clinic has commanded materially more ($100M upfront plus $200M option fee and up to $1.7B total for LegoChem/Janssen) [28]. Preclinical or option-stage bispecific deals sit lower on absolute terms but follow the same royalty and territory-carve-out logic (VelaVigo/Avenzo's ~$750M milestone package) [86]. Any negotiation for OBI's assets, or for a residual Greater China or other regional slice on an already-partnered molecule, would be benchmarked against this template rather than against list prices unique to TROP2.

Net picture. The overwhelming majority of clinically meaningful TROP2 ADC value — all three approved/late-stage assets, LCB84, DB-1305, JSKN016's ex-China rights, GQ1010's ex-China rights, and sac-TMT's ex-China rights — is already spoken for. What remains realistically on the market is narrow: OBI Pharma's OBI-902/OBI-992/OBI-201 franchise is the one clinical-to-preclinical TROP2 (and TROP2-bispecific) family explicitly and currently being shopped, itself already bounded by a Greater-China exclusion inherited from its underlying antibody license; a scatter of undisclosed-status preclinical Chinese assets (GQ1003, Lanier's, RemeGen's,

Tangling's programs) may or may not be available; and a set of Greater-China (or other regional) rights retained by originators after ex-China deals are technically unlicensed but, with the possible exception of GeneQuantum's GQ1010 China rights, show little sign of being actively marketed. The IP landscape reinforces why new entrants gravitate toward differentiated binders or bispecific formats rather than head-on topoisomerase-I-payload competitors: Daiichi Sankyo/AstraZeneca's foundational linker-payload composition patent and its dense combination-patent halo, together with Gilead's parallel combination-therapy estate around the SN-38 chemotype, constrain freedom-to-operate for any new monospecific ADC using a similar payload class, even as a fragmented periphery of 15+ assignees — including several bispecific TROP2 pairings with HER2, EGFR, B7-H3, B7-H4, and PTK7 — indicates that antibody-epitope and novel-payload whitespace still exists for a genuinely new, differentiated licensable asset.

Sources

1 Trodelvy
RegulatoryCore · FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115

2 Trodelvy
RegulatoryCore · EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy

3 immunomedics and everest medicines announce ... - SEC.gov
WebCore · sec.gov
https://www.sec.gov/Archives/edgar/data/722830/000110465919024301/a19-9031_2ex99d1.htm

4 Immunomedics and Everest Medicines Announce Exclusive
WebCore · globenewswire.com · 2019
https://www.globenewswire.com/news-release/2019/04/29/1811184/0/en/immunomedics-and-everest-medicines-announce-exclusive-license-agreement-for-sacituzumab-govitecan-in-east-and-southeast-asia-excluding-japan.html

5 Immunomedics and Everest Medicines Announce ...
WebCore · firstwordpharma.com · 2019
https://firstwordpharma.com/story/4780135

6 Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
WebCore · gilead.com
https://www.gilead.com/news/news-details/2022/gilead-to-acquire-remaining-worldwide-rights-of-trodelvy

7 Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
WebCore · prnewswire.com · 2022
https://www.prnewswire.com/news-releases/everest-medicines-enters-into-agreement-with-gilead-sciences-for-trodelvy-in-asia-territories-301605802.html

8 Everest Medicines inks $455 M worth oncology deal with Gilead Sciences for Asia territories
WebCore · biospectrumasia.com
https://www.biospectrumasia.com/news/25/20876/everest-medicines-inks-455-m-worth-oncology-deal-with-gilead-sciences-for-asia-territories-.html

9 Trodelvy for the Treatment of Advanced Triple-Negative Breast Cancer
WebCore · clinicaltrialsarena.com · 2024
https://www.clinicaltrialsarena.com/projects/trodelvy-sacituzumab-govitecan/

10 Datroway
RegulatoryCore · FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761394

11 Datroway
RegulatoryCore · FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761464

12 Datroway
RegulatoryCore · EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/datroway

13 AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate
WebCore · astrazeneca.com · 2020
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate.html

14 Daiichi Sankyo and AstraZeneca Enter New Global ...
WebCore · daiichisankyo.com · 2020
https://www.daiichisankyo.com/media/press_release/detail/index_3126.html

15 Datopotamab deruxtecan Biologics License Application accepted in the ...
WebCore · astrazeneca.com · 2024
https://www.astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-nonsquamous-nsclc.html

16 Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
WebCore · astrazeneca.com
https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-new-bla-submitted-nsq-bla-withdrawn.html

17 Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201) - Press Releases - Media - Daiichi Sankyo
WebCore · daiichisankyo.com
http://daiichisankyo.com/media/press_release/detail/index_3199.html

18 Blueprint
WebCore · sec.gov · 2019
https://www.sec.gov/Archives/edgar/data/901832/000165495419003592/a4052u.htm

19 Daiichi Sankyo and AstraZeneca Announce Global ...
WebCore · prnewswire.com · 2019
https://www.prnewswire.com/news-releases/daiichi-sankyo-and-astrazeneca-announce-global-development-and-commercialization-collaboration-for-daiichi-sankyos-her2-targeting-antibody-drug-conjugate-fam--trastuzumab-deruxtecan-ds-8201-300820766.html

20 Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan ...
WebCore · prnewswire.com · 2024
https://www.prnewswire.com/news-releases/kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-sac-tmt-approved-for-marketing-by-nmpa-of-china-for-2l-advanced-or-metastatic-tnbc-302317233.html

21 an upfront payment of $175 million
WebCore · sec.gov
https://www.sec.gov/Archives/edgar/data/310158/000162828023005061/R14.htm

22 Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) | Nasdaq
WebCore · nasdaq.com · 2025
https://www.nasdaq.com/press-release/merck-enters-research-and-development-funding-agreement-blackstone-life-sciences

23 Kelun-Biotech Announces Breakthrough Therapy ...
WebCore · prnewswire.com · 2026
https://www.prnewswire.com/apac/news-releases/kelun-biotech-announces-breakthrough-therapy-designation-granted-in-china-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-immunotherapy-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc-302652496.html

24 Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) - Merck.com
WebCore · merck.com · 2026
http://merck.com/news/merck-enters-into-research-and-development-funding-agreement-with-blackstone-life-sciences-for-sacituzumab-tirumotecan-sac-tmt

25 Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer - Merck.com
WebCore · merck.com · 2026
https://www.merck.com/news/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer

26 Merck pays $35M to Kelun-Biotech for rights to investigational antibody drug conjugate - The Cancer Letter
WebCore · cancerletter.com · 2022
https://cancerletter.com/drugs-and-targets/20220729_9b/

27 https://www.sec.gov/Archives/edgar/data/310158/000162828023015990/R10.htm
WebCore · sec.gov
https://www.sec.gov/Archives/edgar/data/310158/000162828023015990/R10.htm

28 LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC | Johnson & Johnson Innovation
WebCore · jnjinnovation.com
https://jnjinnovation.com/news/press-releases/legochem-biosciences-announces-license-agreement-for-lcb84-trop2targeted-adc

29 LegoChem inks $1.7 billion ADC deal with Janssen | The Pharmaletter
WebCore · thepharmaletter.com
https://www.thepharmaletter.com/biotech-news/legochem-inks-1-7-billion-adc-deal-with-janssen

30 J&J jumps on ADC from LegoChem in deal that could pay out over ...
WebCore · firstwordpharma.com · 2023
https://firstwordpharma.com/story/5813200

31 J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem
WebCore · pharmaceutical-technology.com · 2023
https://www.pharmaceutical-technology.com/news/jj-jumps-on-adc-train-signs-1-7bn-licensing-deal-with-legochem

32 Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
WebCore · prnewswire.com · 2024
https://www.prnewswire.com/news-releases/biosions-partner-obi-pharma-announces-fda-clearance-of-ind-application-for-a-phase-12-study-of-obi-992-trop2-adc-302028402.html

33 BSI-992 - Drug Targets, Indications, Patents
WebCore · synapse.patsnap.com · 2026
https://synapse.patsnap.com/drug/b27d76fa5e244d56bb8e3aef9eda0a87

34 OBI Pharma Announces Phase 1/2 Study Initiation for OBI ...
WebCore · firstwordpharma.com · 2024
https://firstwordpharma.com/story/5866126

35 OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial - OBI Pharma 台灣浩鼎
WebCore · obipharma.com · 2024
https://www.obipharma.com/announcement/obi-992-trop2-adc-has-been-granted-by-us-fda-to-proceed-to-phase-i-ii-human-clinical-trial

36 OBI-992 | BSI-992
WebCore · adcreview.com · 2024
https://www.adcreview.com/drugmap/obi-992-bsi-992/

37 Development and Validation of Pharmacokinetic Assays for ...
WebCore · papers.ssrn.com
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5369400

38 OBI Pharma
WebCore · s3.ap-northeast-1.amazonaws.com
https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2025/06/2025-OBI%E8%82%A1%E6%9D%B1%E6%9C%83_%E8%8B%B1%E6%96%87%E7%89%88_Final.pdf

39 Pipeline - OBI Pharma
WebCore · obipharma.com
http://obipharma.com/what-we-do/pipeline-overview

40 OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors - OBI Pharma
WebCore · obipharma.com
http://obipharma.com/news/obi-pharma-announces-phase-1-2-study-initiation-for-obi-902

41 OBI has submitted the IND application of a Phase I/II human clinical ...
WebCore · obipharma.com
https://www.obipharma.com/announcement/obi-has-submitted-the-ind-application-of-a-phase-i-ii-human-clinical-trial-for-obi-902-trop2-adc-to-the-us-fda

42 OBI Pharma Announces U.S. FDA Clearance of IND Application for ...
WebCore · obipharma.com
https://www.obipharma.com/news/obi-pharma-announces-u-s-fda-clearance-of-ind-application-for-a-phase-1-2-study-of-obi-902

43 [PDF] OBI Pharma - Amazon S3
WebCore · s3.ap-northeast-1.amazonaws.com
https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2025/12/OBI-Investors-Meeting-2025-deck_English_FINAL-2.pdf

44 Pipeline Chart 28 Apr 2026
WebCore · s3.ap-northeast-1.amazonaws.com · 2026
http://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2026/04/Pipeline-Chart_28-Apr-2026.pdf

45 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
WebCore · biontech.com · 2024
http://biontech.com/us/en/home/mediaroom/news/press-releases/2024/01/biontech-and-dualitybio-receive-fda-fast-track-designation-next.html

46 DualityBio Expands Global Strategic Partnership with ...
WebCore · prnewswire.com · 2023
https://www.prnewswire.com/news-releases/dualitybio-expands-global-strategic-partnership-with-biontech-to-accelerate-development-of-a-third-antibody-drug-conjugate-therapeutics-for-solid-tumors-301894397.html

47 BioNTech and Duality Bio add another investigational drug ...
WebCore · pharmaceutical-technology.com · 2023
https://www.pharmaceutical-technology.com/news/biontech-duality-bio-investigational-drug-oncology-partnership

48 Global
WebCore · en.dualitybiologics.com
https://en.dualitybiologics.com/global/index.html

49 Sacituzumab Drozuntecan - Drug Targets, Indications, Patents - Synapse
WebCore · synapse.patsnap.com · 2026
https://synapse.patsnap.com/drug/07bdc1e1c3f74753bed0c9fd0b3dd1fb

50 DualityBio Presented Early Clinical and Preclinical Data for Novel ADC Therapy Candidates at AACR 2025
WebCore · en.dualitybiologics.com
http://en.dualitybiologics.com/news/587.html

51 DB-1305 /BNT325
WebCore · en.dualitybiologics.com
http://en.dualitybiologics.com/17335757308177/newpath17336570213359/15.html

52 sacituzumab drozuntecan (BNT325) / DualityBio, BioNTech
WebCore · delta.larvol.com
https://delta.larvol.com/Products/?ProductId=4ee57bac-2175-4072-9cb9-03dff73bf0a8

53 Sutro Biopharma Reports Full Year 2025 Financial Results ...
WebCore · ir.sutrobio.com · 2026
https://ir.sutrobio.com/press-releases/detail/231/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights

54 Sutro Biopharma Presents Promising Preclinical Data ...
WebCore · ir.sutrobio.com · 2026
https://ir.sutrobio.com/press-releases/detail/232/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026

55 Sutro Biopharma Q2 2026 results and ADC pipeline | STRO 8-K Filing
WebCore · stocktitan.net
http://stocktitan.net/sec-filings/STRO/8-k-sutro-biopharma-inc-reports-material-event-0f1b08631ec4.html

56 Pipeline of Next-Generation Single- and Dual-Payload ADCs
WebCore · sutrobio.com · 2026
https://www.sutrobio.com/wp-content/uploads/2026/05/STRO_May2026_PIPELINE_05.14.2026.pdf

57 Untitled
WebCore · alphamabonc.com
http://alphamabonc.com/en/html/news/2826.html

58 JSKN016-Alphamab Oncology
WebCore · alphamabonc.com
https://www.alphamabonc.com/en/pipeline/jskn016.html

59 Pathos AI Licenses Alphamab's TROP2/HER3 Bispecific ADC, JSKN016
WebCore · biopharminternational.com · 2026
https://www.biopharminternational.com/view/pathos-ai-alphamab-trop2-her3-bispecific-adc-jskn016

60 Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - BioSpace
WebCore · biospace.com
http://biospace.com/press-releases/pathos-ai-enters-global-licensing-agreement-with-alphamab-oncology-on-jskn016-a-first-in-class-trop2-her3-bispecific-adc

61 Alphamab Oncology Reports 2026 Interim Results and Business Highlights-Alphamab Oncology
WebCore · alphamabonc.com
http://alphamabonc.com/en/html/news/2834.html

62 PIPELINE_GeneQuantum
WebCore · genequantum.com
https://www.genequantum.com/pipeline.html

63 Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare
WebCore · prnewswire.com · 2023
http://prnewswire.com/news-releases/pyramid-biosciences-expands-oncology-pipeline-with-in-licensing-of-gq1010-a-potential-best-in-class-trop2-targeted-antibody-drug-conjugate-adc-from-genequantum-healthcare-301796003.html

64 GQ-1010 - Drug Targets, Indications, Patents
WebCore · synapse.patsnap.com · 2026
https://synapse.patsnap.com/drug/7dade9b3b4b44f2a92b68e6b582c003e

65 BHV-1510 / GeneQuantum Healthcare, Biohaven
WebCore · delta.larvol.com
https://delta.larvol.com/Products/?ProductId=9b68b4e1-f1b8-4566-8ffc-0a3b618fe1f9

66 ABOUT US_GeneQuantum
WebCore · genequantum.com
http://genequantum.com/about.html

67 Kelun's TROP2 ADC Snags China Approval For 2L NSCLC
WebCore · insights.citeline.com · 2025
https://insights.citeline.com/scrip/new-products/keluns-trop2-adc-snags-china-approval-for-2l-nsclc-OTOFEIC5BBAHVCPQPROLDQCU5Q/

68 - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
WebCore · en.kelun-biotech.com
https://en.kelun-biotech.com/aboutUs.aspx

69 Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
WebCore · prnewswire.com · 2025
https://www.prnewswire.com/news-releases/kelun-biotech-presented-trop2-adc-sacituzumab-tirumotecan-results-from-multiple-clinical-studies-at-the-2025-cchio-congress-302609623.html

70 Merck strikes 2nd ADC deal with Kelun-Biotech, paying $35M
WebCore · fiercebiotech.com · 2022
https://www.fiercebiotech.com/biotech/merck-strikes-second-adc-deal-kelun-biotech-paying-35m-rights-unnamed-asset

71 Sorrento Announces That Its Subsidiary Levena and Its Partner ...
WebCore · biospace.com · 2021
https://www.biospace.com/sorrento-announces-that-its-subsidiary-levena-and-its-partner-escugen-have-received-clearance-to-begin-clinical-trials-with-anti-trop-2-antibody-drug-conjugate-for-multiple-solid-tumors

72 Sorrento Announces That Its Subsidiary Levena and Its
WebCore · globenewswire.com · 2021
https://www.globenewswire.com/news-release/2021/07/21/2266761/0/en/sorrento-announces-that-its-subsidiary-levena-and-its-partner-escugen-have-received-clearance-to-begin-clinical-trials-with-anti-trop-2-antibody-drug-conjugate-for-multiple-solid-t.html

73 Shanghai Escugen Biotechnology Co., Ltd., a partner of
WebCore · globenewswire.com · 2023
https://www.globenewswire.com/news-release/2023/06/05/2682017/0/en/shanghai-escugen-biotechnology-co-ltd-a-partner-of-levena-biopharma-a-sorrento-company-releases-positive-results-from-a-first-in-human-study-of-esg401-a-trop2-antibody-drug-conjuga.html

74 Phase 1a study of ESG401, a Trop2 antibody-drug ...
WebCore · pubmed.ncbi.nlm.nih.gov
https://pubmed.ncbi.nlm.nih.gov/39216478/

75 OQY-3258 / Escugen Biotechnology, Sorrento, Oqory
WebCore · delta.larvol.com
https://delta.larvol.com/Products/?ProductId=4dca822f-2007-417d-a832-9eeae6c1ad0c

76 OQY-3258, ESG401, ESG-401, STI-3258 Clinical ADC
WebCore · db.antibodysociety.org
https://db.antibodysociety.org/db0/612/

77 OQY-3258, ESG401, ESG-401, STI-3258 Clinical ADC
WebCore · db.antibodysociety.org
https://db.antibodysociety.org/home/tabsdb/tabs/db0/612

78 ESG-401 - Drug Targets, Indications, Patents
WebCore · synapse.patsnap.com
https://synapse.patsnap.com/drug/6b49ef5152bb42fd953801f38e979dda

79 Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China
WebCore · prnewswire.com · 2024
https://www.prnewswire.com/apac/news-releases/alphamab-oncology-and-cspc-achieved-a-licensing-agreement-on-anti-her2-bispecific-adc-jskn003-in-mainland-china-302262017.html

80 Alphamab Oncology and CSPC Achieved a Licensing ...
WebCore · alphamabonc.com
https://www.alphamabonc.com/en/html/news/2614.html

81 CORRECTING and REPLACING LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
WebCore · businesswire.com · 2023
https://www.businesswire.com/news/home/20231225841872/en/CORRECTING-and-REPLACING-LegoChem-Biosciences-Announces-License-Agreement-for-LCB84-Trop2-Targeted-ADC

82 LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal
WebCore · kedglobal.com · 2023
https://www.kedglobal.com/bio-pharma/newsView/ked202312260001

83 LegoChem inks $1.7 billion license-out deal with Janssen for ADC ...
WebCore · koreabiomed.com · 2023
https://www.koreabiomed.com/news/articleView.html?idxno=22890

84 From licensing deals to patients: LigaChem and ABL Bio shift focus to clinical proof < Bio < Article - Korea Biomedical Review
WebCore · koreabiomed.com · 2026
https://www.koreabiomed.com/news/articleView.html?idxno=32678

85 ABL Bio
WebCore · ablbio.com
https://www.ablbio.com/en/company/news_view/360?keyword=

86 VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
WebCore · prnewswire.com · 2024
https://www.prnewswire.com/news-releases/velavigo-announces-exclusive-option-agreement-with-avenzo-to-license-a-potential-first-in-class-nectin4trop2-bispecific-antibody-drug-conjugate-302308483.html

87 VelaVigo Secures Exclusive Licensing Option for Nectin4/TROP2 Bispecific Antibody-Drug Conjugate with Avenzo
WebCore · synapse.patsnap.com · 2024
https://synapse.patsnap.com/article/velavigo-secures-exclusive-licensing-option-for-nectin4trop2-bispecific-antibody-drug-conjugate-with-avenzo

88 Goodwin Advises VelaVigo on Exclusive Option Agreement with Avenzo to License Nectin4/TROP2 Bispecific Antibody-Drug Conjugate for Up To $750 Million | News & Events | Goodwin
WebCore · goodwinlaw.com · 2024
https://www.goodwinlaw.com/en/news-and-events/news/2024/12/announcements-lifesciences-goodwin-advises-velavigo-on-exclusive-option-with-avenzo

89 VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - BioSpace
WebCore · biospace.com · 2025
https://www.biospace.com/press-releases/velavigo-announces-exclusive-option-agreement-with-avenzo-to-license-a-potential-first-in-class-nectin4-trop2-bispecific-antibody-drug-conjugate

90 Exclusive option agreement with VelaVigo to license a ...
WebCore · avenzotx.com · 2024
https://avenzotx.com/press-releases/avenzo-therapeutics-provides-corporate-update-and-announces-closing-of-series-a-a-1-financing/

91 AVZO-103 / VelaVigo, Avenzo Therap
WebCore · delta.larvol.com
https://delta.larvol.com/Products/?ProductId=89b7c38b-305d-4d4d-97d2-7609736ab7d9

92 VelaVigo
WebCore · thepharmaletter.com · 2025
https://www.thepharmaletter.com/velavigo

93 PIPELINE_GeneQuantum
WebCore · genequantum.com
http://genequantum.com/pipeline.html

94 Pyramid Biosciences Inc. - Page 1 | BioWorld
WebCore · bioworld.com
https://www.bioworld.com/keywords/8464-pyramid-biosciences-inc

95 Pyramid Biosciences and GeneQuantum Healthcare ...
WebCore · firstwordpharma.com · 2023
https://firstwordpharma.com/story/5729449

96 GeneQuantum Healthcare (Suzhou) Co. Ltd.
WebCore · synapse.patsnap.com
https://synapse.patsnap.com/organization/f4e1a564e05a59d8fe249907ee2c2a5a

97 GQ1003 - TROP2
WebCore · adcreview.com
https://www.adcreview.com/drugmap/gq1003-trop2/

98 GeneQuantum and InxMed have reached a technology ...
WebCore · genequantum.com · 2023
https://www.genequantum.com/news_report/158.html

99 Henlius Licenses Phase 3 Innovative HER2 ADC from ...
WebCore · henlius.com · 2025
https://www.henlius.com/en/NewsDetails-5387-26.html

100 Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to ...
WebCore · prnewswire.com · 2021
https://www.prnewswire.com/news-releases/biosion-inc-licenses-bsi04702-an-anti-trop-2-mab-to-obi-pharma-inc-for-worldwide-development-and-commercialization-rights-as-an-antibody-drug-conjugate--and-other-derivative-products-301442963.html

101 Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to ...
WebCore · biospace.com · 2021
https://www.biospace.com/biosion-inc-licenses-bsi04702-an-anti-trop-2-mab-to-obi-pharma-inc-for-worldwide-development-and-commercialization-rights-as-an-antibody-drug-conjugate-and-other-derivative-products

102 Press Release - Investor Overview - Aclaris Therapeutics
WebCore · investor.aclaristx.com · 2024
https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-exclusive-global-license

103 Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement // Cooley // Global Law Firm
WebCore · cooley.com · 2026
https://www.cooley.com/news/coverage/2024/2024-11-18-aclaris-therapeutics-announces-global-license-agreement-with-biosion

104 ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
WebCore · finance.yahoo.com · 2024
https://finance.yahoo.com/news/acrs-stock-licensing-deal-biosion-141900379.html

105 Pathos AI pads pipeline with $2.2B Alphamab deal, AZ pact
WebCore · fiercebiotech.com · 2026
http://fiercebiotech.com/biotech/pathos-ai-pads-pipeline-22b-alphamab-deal-plus-astrazeneca-pact

106 Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC
WebCore · businesswire.com
http://businesswire.com/news/home/20260803012674/en/Pathos-AI-Enters-Global-Licensing-Agreement-with-Alphamab-Oncology-on-JSKN016-a-First-in-Class-TROP2HER3-Bispecific-ADC

107 Shanghai Escugen Biotechnology Co., Ltd., a partner of ...
WebCore · firstwordpharma.com · 2023
https://firstwordpharma.com/story/5747845

108 Levena Suzhou Biopharma Co. Ltd.
WebCore · synapse.patsnap.com
https://synapse.patsnap.com/organization/efdca7968008e5b6499c8d2beacc287c

109 Levena Suzhou Biopharma Co. Ltd.
WebCore · synapse-patsnap-com.libproxy1.nus.edu.sg
https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/efdca7968008e5b6499c8d2beacc287c

110 TROP2 ADC(Lanier) - Drug Targets, Indications, Patents - Synapse
WebCore · synapse.patsnap.com
https://synapse.patsnap.com/drug/fe615fd971f201f51242fe981a632476

111 Biparatopic trop2-ADC(RemeGen) - Drug Targets, Indications, Patents - Synapse
WebCore · synapse.patsnap.com
https://synapse.patsnap.com/drug/eaf93e82b01d4e15a9c77975c61b8e65

112 Anti-TROP-2 ADC(GlycanLink Biotech)
WebCore · synapse.patsnap.com
https://synapse.patsnap.com/drug/6f3cfd9ddc1c482ba9eb4081aa1de87b

113 The ADC Specialty Company
WebCore · levenabiopharma.com
https://www.levenabiopharma.com/en/home

114 TROP2 - ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
PatentCore · 다이이찌 산쿄 가부시키가이샤, 홋카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 · 2025
https://www.lens.org/lens/patent/042-406-083-790-224

115 TROP2 - ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
PatentCore · DAIICHI SANKYO CO LTD, UNIV SAPPORO MEDICAL · 2025
https://www.lens.org/lens/patent/136-998-051-928-794

116 Anti-TROP2 antibody-drug conjugate
PatentCore · DAIICHI SANKYO CO LTD, UNIV SAPPORO MEDICAL · 2019
https://www.lens.org/lens/patent/008-180-873-950-42X

117 TROP2 - ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
PatentCore · DAIICHI SANKYO CO LTD, UNIV SAPPORO MEDICAL · 2023
https://www.lens.org/lens/patent/107-777-256-530-818

118 TROP2 - ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
PatentCore · DAIICHI SANKYO CO LTD, UNIV SAPPORO MEDICAL · 2021
https://www.lens.org/lens/patent/013-155-924-448-277

119 METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE
PatentCore · DAIICHI SANKYO CO LTD · 2023
https://www.lens.org/lens/patent/050-170-136-457-997

120 DOSAGE OF AN ANTIBODY-DRUG CONJUGATE
PatentCore · DAIICHI SANKYO CO LTD · 2023
https://www.lens.org/lens/patent/122-673-414-587-957

121 COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH PARP INHIBITOR
PatentCore · DAIICHI SANKYO CO LTD · 2022
https://www.lens.org/lens/patent/023-834-852-942-053

122 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR
PatentCore · ASTRAZENECA UK LTD, DAIICHI SANKYO CO LTD · 2025
https://www.lens.org/lens/patent/178-230-520-595-490

123 COMBINATION OF ANTIBODY-DRUG CONJUGATES AND DNMT INHIBITORS
PatentCore · DAIICHI SANKYO CO LTD, ASTRAZENECA UK LTD · 2024
https://www.lens.org/lens/patent/189-136-566-888-799

124 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND BISPECIFIC CHECKPOINT INHIBITOR
PatentCore · ASTRAZENECA UK LTD, DAIICHI SANKYO CO LTD · 2025
https://www.lens.org/lens/patent/040-244-376-506-037

125 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND BISPECIFIC CHECKPOINT INHIBITOR
PatentCore · ASTRAZENECA UK LTD, DAIICHI SANKYO CO LTD · 2024
https://www.lens.org/lens/patent/062-644-780-622-639

126 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1/TIM-3 BISPECIFIC BINDING PROTEIN
PatentCore · ASTRAZENECA UK LTD, DAIICHI SANKYO CO LTD · 2025
https://www.lens.org/lens/patent/172-332-877-007-355

127 A SCORING METHOD FOR AN ANTI-TROP2 ANTIBODY-DRUG CONJUGATE THERAPY
PatentCore · ASTRAZENECA UK LTD, DAIICHI SANKYO CO LIMITED · 2026
https://www.lens.org/lens/patent/054-007-332-923-444

128 A SCORING METHOD FOR AN ANTI-TROP2 ANTIBODY DRUG CONJUGATE THERAPY
PatentCore · ASTRAZENECA UK LTD, DAIICHI SANKYO CO LTD · 2026
https://www.lens.org/lens/patent/013-974-130-963-68X

129 COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
PatentCore · ASTRAZENECA UK LTD, DAIICHI SANKYO CO LIMITED · 2026
https://www.lens.org/lens/patent/109-441-432-899-723

130 THERAPY FOR TREATING BLADDER CANCER
PatentCore · GILEAD SCIENCES INC · 2024
https://www.lens.org/lens/patent/170-348-415-052-200

131 COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS
PatentCore · GILEAD SCIENCES INC, ARCUS BIOSCIENCES INC · 2023
https://www.lens.org/lens/patent/119-309-668-347-890

132 COMBINATION THERAPY FOR TREATING TUMOR ANTIGEN EXPRESSING CANCERS
PatentCore · GILEAD SCIENCES INC, ARCUS BIOSCIENCES INC · 2023
https://www.lens.org/lens/patent/052-021-859-521-191

133 COMBINATION THERAPY FOR TREATING TUMOR ANTIGEN EXPRESSING CANCERS
PatentCore · GILEAD SCIENCES INC, ARCUS BIOSCIENCES INC · 2025
https://www.lens.org/lens/patent/191-740-276-463-082

134 COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING PROSTATE CANCERS
PatentCore · GILEAD SCIENCES INC · 2024
https://www.lens.org/lens/patent/085-084-899-746-892

135 COMBINATION MCL-1 INHIBITORS WITH ANTI-BODY DRUG CONJUGATES
PatentCore · GILEAD SCIENCES INC · 2022
https://www.lens.org/lens/patent/175-167-847-489-376

136 Combination MCL-1 inhibitors with anti-body drug conjugates
PatentCore · GILEAD SCIENCES INC · 2024
https://www.lens.org/lens/patent/089-105-963-681-241

137 COMBINATION MCL-1 INHIBITORS WITH ANTI-BODY DRUG CONJUGATES
PatentCore · GILEAD SCIENCES INC · 2022
https://www.lens.org/lens/patent/126-819-568-194-771

138 COMBINATION MCL-1 INHIBITORS WITH ANTI-CANCER AGENTS
PatentCore · GILEAD SCIENCES INC · 2023
https://www.lens.org/lens/patent/199-213-240-339-406

139 ANTI-TROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP2) ANTIBODIES AND ANTIBODY DRUG CONJUGATES COMPRISING SAME
PatentCore · CSPC MEGALITH BIOPHARMACEUTICAL CO LTD · 2022
https://www.lens.org/lens/patent/126-766-292-141-137

140 Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same
PatentCore · CSPC MEGALITH BIOPHARMACEUTICAL CO LTD · 2025
https://www.lens.org/lens/patent/154-963-898-241-907

141 ANTI-TROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP2) ANTIBODIES AND ANTIBODY DRUG CONJUGATES COMPRISING SAME
PatentCore · CSPC DOPHEN CORP · 2020
https://www.lens.org/lens/patent/005-509-940-115-160

142 COMPOUNDS AND METHODS FOR THE TREATMENT OF TROP2 POSITIVE DISEASES
PatentCore · BIO THERA SOLUTIONS LTD · 2019
https://www.lens.org/lens/patent/071-208-454-039-056

143 Compounds and methods for the treatment of TROP2 positive diseases
PatentCore · BIO THERA SOLUTIONS LTD · 2021
https://www.lens.org/lens/patent/103-583-829-900-089

144 METHOD FOR TREATING SOLID TUMOR
PatentCore · BIO THERA SOLUTIONS LTD · 2025
https://www.lens.org/lens/patent/026-711-233-437-84X

145 METHOD FOR TREATING SOLID TUMOR
PatentCore · BIO THERA SOLUTIONS LTD · 2025
https://www.lens.org/lens/patent/024-016-353-008-081

146 DRUG CONJUGATE AND USE THEREOF
PatentCore · BIO THERA SOLUTIONS LTD · 2024
https://www.lens.org/lens/patent/175-554-511-621-492

147 DRUG CONJUGATE AND USE THEREOF
PatentCore · BIO THERA SOLUTIONS LTD · 2024
https://www.lens.org/lens/patent/132-370-947-693-650

148 ANTIBODIES BINDING TROP2 AND USES THEREOF
PatentCore · BIOSION INC · 2022
https://www.lens.org/lens/patent/073-077-551-037-162

149 ANTIBODIES BINDING TROP2 AND USES THEREOF
PatentCore · BIOSION INC · 2024
https://www.lens.org/lens/patent/058-713-222-769-910

150 NANOBODIES BINDING TROP2 AND USES THEREOF
PatentCore · BIOSION INC · 2022
https://www.lens.org/lens/patent/150-202-254-400-19X

151 ANTIBODY-DRUG CONJUGATE TARGETING TROP2, AND PREPARATION METHOD AND USE THEREFOR
PatentCore · FORTVITA BIOLOGICS INC · 2026
https://www.lens.org/lens/patent/165-446-946-801-440

152 ANTIBODY DRUG CONJUGATES TARGETING B7-H3 AND TROP2 AND THE USE THEREOF
PatentCore · FORTVITA BIOLOGICS INC · 2025
https://www.lens.org/lens/patent/119-275-663-262-924

153 ANTIBODY AND ANTIBODY DRUG CONJUGATES TARGETING TO TROP2 AND B7H4 AND THE USE THEREOF
PatentCore · INNOVENT BIOLOGICS SUZHOU CO LTD, FORTVITA BIOLOGICS INC · 2026
https://www.lens.org/lens/patent/058-176-797-109-293

154 ANTIBODY-DRUG CONJUGATES TARGETING EGFR/C-MET AND PREPARATION METHODS AND USES THEREOF
PatentCore · SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD · 2025
https://www.lens.org/lens/patent/080-089-491-340-97X

155 ANTIBODY-DRUG CONJUGATES TARGETING EGFR/C-MET AND PREPARATION METHODS AND USES THEREOF
PatentCore · SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD · 2025
https://www.lens.org/lens/patent/004-416-185-262-562

156 EGFR/C-MET BISPECIFIC BINDING PROTEIN AND USE THEREOF
PatentCore · SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD · 2025
https://www.lens.org/lens/patent/077-923-058-098-784

157 ANTIBODY-DRUG CONJUGATE
PatentCore · BEIJING JOINN BIOLOGICS CO LTD · 2025
https://www.lens.org/lens/patent/032-977-653-414-666

158 IMMUNOCONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF
PatentCore · JOINN BIOLOGICS US INC · 2025
https://www.lens.org/lens/patent/161-281-541-561-84X

159 ANTI-HER2/TROP2 ANTIBODIES AND USES THEREOF
PatentCore · BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD · 2023
https://www.lens.org/lens/patent/164-140-385-791-714

160 ANTI-HER2/TROP2 ANTIBODIES AND USES THEREOF
PatentCore · BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD · 2025
https://www.lens.org/lens/patent/190-199-151-782-152

161 METHODS FOR PREPARING ANTIBODY-DRUG CONJUGATES
PatentCore · BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD · 2024
https://www.lens.org/lens/patent/059-798-904-014-832

162 ANTIBODIES AND USES THEREOF
PatentCore · BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD · 2024
https://www.lens.org/lens/patent/123-565-406-230-163

163 ANTIBODIES AND USES THEREOF
PatentCore · Biocytogen Pharmaceuticals (Beijing) Co., Ltd. · 2026
https://www.lens.org/lens/patent/126-537-155-675-133

164 ANTI-HER2/TROP2 ANTIBODIES AND USES THEREOF
PatentCore · BRIGHT BIOLOGICS LLC, HANGZHOU BAILITE BIOPHARMACEUTICAL CO LTD · 2024
https://www.lens.org/lens/patent/002-907-973-906-692

165 ANTI-HER2/TROP2 ANTIBODIES AND USES THEREOF
PatentCore · BRIGHT BIOLOGICS LLC · 2026
https://www.lens.org/lens/patent/033-923-896-979-971

166 ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF
PatentCore · XADCERA BIOPHARMACEUTICAL SUZHOU CO LTD · 2024
https://www.lens.org/lens/patent/116-685-199-725-819

167 ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF
PatentCore · XADCERA BIOPHARMACEUTICAL SUZHOU CO LTD · 2026
https://www.lens.org/lens/patent/174-377-591-182-74X

168 ENGINEERED ANTI-TROP2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
PatentCore · WUXI BIOLOGICS SHANGHAI CO LTD, WUXI BIOLOGICS IRELAND LTD · 2022
https://www.lens.org/lens/patent/062-209-242-123-596

169 ANTI-TROP2 ANTIBODY COMBINATION THERAPIES AND METHODS OF USE THEREOF
PatentCore · UNIV TEXAS · 2023
https://www.lens.org/lens/patent/029-899-141-528-134

170 ANTI-TROP2 ANTIBODY COMBINATION THERAPIES AND METHODS OF USE THEREOF
PatentCore · UNIV TEXAS · 2025
https://www.lens.org/lens/patent/062-440-429-755-472

171 TROP2-TARGETING ANTIBODIES AND USES THEREOF
PatentCore · UNIV TEXAS · 2025
https://www.lens.org/lens/patent/117-286-543-061-432

172 ANTI-TROP2 ANTIBODIES
PatentCore · AGENCY SCIENCE TECH & RES · 2026
https://www.lens.org/lens/patent/119-378-503-355-138

173 ANTI-TROP2 ANTIBODIES
PatentCore · AGENCY SCIENCE TECH & RES · 2025
https://www.lens.org/lens/patent/177-216-102-469-187

174 ANTI-TROP2 ANTIGEN-BINDING MOLECULES
PatentCore · AGENCY SCIENCE TECH & RES · 2025
https://www.lens.org/lens/patent/034-386-050-840-437

175 ANTIBODY COMPOSITIONS COMPRISING FC MUTATIONS AND SITE-SPECIFIC CONJUGATION PROPERTIES
PatentCore · TAE LIFE SCIENCES · 2021
https://www.lens.org/lens/patent/052-874-363-513-459

176 Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
PatentCore · TAE LIFE SCIENCES · 2024
https://www.lens.org/lens/patent/049-317-669-145-847

177 Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereof
PatentCore · TAE LIFE SCIENCES, TAE LIFE SCIENCES LLC · 2026
https://www.lens.org/lens/patent/149-155-655-616-501

178 TROP2-BINDING MOLECULES
PatentCore · HUMMINGBIRD BIOSCIENCE PTE LTD · 2026
https://www.lens.org/lens/patent/184-768-795-173-889

179 ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY
PatentCore · MYRICX PHARMA LTD · 2025
https://www.lens.org/lens/patent/094-313-081-076-282

180 ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY
PatentCore · MYRICX PHARMA LTD · 2026
https://www.lens.org/lens/patent/120-581-824-192-56X

181 Merck and Kelun-Biotech Announce Exclusive License and ...
WebCore · merck.com · 2022
https://www.merck.com/news/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer/

182 Merck Enters into Research and Development Funding ...
WebCore · merck.com · 2025
https://www.merck.com/news/merck-enters-into-research-and-development-funding-agreement-with-blackstone-life-sciences-for-sacituzumab-tirumotecan-sac-tmt

183 Merck bags $700M from Blackstone, spends $150M to regain asset
WebCore · fiercebiotech.com · 2025
https://www.fiercebiotech.com/biotech/merck-writes-tale-2-checks-bagging-700m-blackstone-while-spending-150m-regain-asset

184 Legochem inks landmark $1.7B deal with Janssen for ADC drug
WebCore · bioworld.com
https://www.bioworld.com/articles/704214-legochem-inks-landmark-17b-deal-with-janssen-for-adc-drug

185 Legochem inks landmark $1.7B deal with Janssen for ADC ...
WebCore · bioworld.com
https://www.bioworld.com/articles/704120-legochem-inks-landmark-17b-deal-with-janssen-for-adc-drug

186 LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate-LaNova
WebCore · lanovamedicines.com
https://www.lanovamedicines.com/en/news-center/press-release/62.html

187 LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
WebCore · prnewswire.com
http://prnewswire.com/news-releases/lanova-medicines-announces-global-exclusive-license-agreement-with-astrazeneca-for-lm-305-a-novel-gprc5d-targeting-antibody-drug-conjugate-301823364.html

188 LaNova Medicines, AstraZeneca sign licence deal for LM- ...
WebCore · pharmaceutical-technology.com · 2023
https://www.pharmaceutical-technology.com/news/lanova-medicines-astrazeneca-lm-305/

189 Fierce Pharma Asia—Licensing deal flow, China crackdown warning and ESMO readouts | Fierce Pharma
WebCore · fiercepharma.com · 2025
https://www.fiercepharma.com/pharma/fierce-pharma-asia-licensing-deal-flow-china-crackdown-warning-and-esmo-readouts

190 Roche Kicks Off 2025 Committing a Potential $1B for Another ADC From China - BioSpace
WebCore · biospace.com · 2025
https://www.biospace.com/business/roche-kicks-off-2025-committing-a-potential-1b-for-another-adc-from-china

191 Out-licensing Deals Between Chinese Pharma and Global ...
WebCore · pharmexec.com · 2024
https://www.pharmexec.com/view/out-licensing-deals-chinese-pharma-global-companies-heating-up

192 In-Licensing China Biotech Assets: Strategic Guide 2026
WebCore · visionlifesciences.com · 2026
https://visionlifesciences.com/insights/in-licensing-biotech-assets-from-china